<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04882579</url>
  </required_header>
  <id_info>
    <org_study_id>PulmonaryEmbolismPoCUSOdense</org_study_id>
    <nct_id>NCT04882579</nct_id>
  </id_info>
  <brief_title>Point-of-care Ultrasound in Suspected Pulmonary Embolism</brief_title>
  <official_title>Point-of-care Ultrasound in the Diagnostic Work-up of Suspected Pulmonary Embolism - a Multicenter Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Snedkermester Sophus Jacobsen and hustru Astrid Jacobsens Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Odense Patient Data Explorative Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pulmonary embolism (PE) is a common cardiovascular condition with an estimated incidence of&#xD;
      0.60 to 1.12 per 1000 inhabitants in the United States of America, and the diagnosis is&#xD;
      challenging as patients with PE present with a wide array of symptoms.&#xD;
&#xD;
      Computed tomography pulmonary angriography (CTPA) and lung ventilation-perfusion scintigraphy&#xD;
      (VQ) are considered the gold-standards in PE-diagnostics but may not always be feasible. CTPA&#xD;
      is contraindicated by contrast allergy or renal failure and both modalities require&#xD;
      involvement of multiple staff-members and transport of the patient. Lung scintigraphy cannot&#xD;
      be performed in an emergency situation, with unstable patients and patients unable to comply&#xD;
      to the examination.&#xD;
&#xD;
      Ultrasound represent a possible tool in confirming or dismissing clinical PE suspicion.&#xD;
      Ultrasound is non-invasive and can be performed bedside by the clinician, an approach known&#xD;
      as point-of-care ultrasound (PoCUS), reducing both time, radiation-exposure and costs.&#xD;
&#xD;
      The aim of this study is to investigate whether integrating cardiac, lung and deep venous&#xD;
      ultrasound in the clinical evaluation of suspected PE reduces the need for referral to CTPA&#xD;
      or lung scintigraphy, during emergency department work up, while maintaining safety&#xD;
      standards.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>150 patients with suspected pulmonary embolism, requiring CTPA or VQ to finally confirm or dismiss the diagnosis will be enrolled and randomized 1:1 to receive a multiorgan ultrasound investigation or continue to CTPA or VQ as planned.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients referred to CTPA or VQ after multiorgan PoCUS</measure>
    <time_frame>Up to 24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events in the intervention and control group after inclusion, including readmission, serious bleeding or death</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hours until initiation of relevant treatment after clinical evaluation in the control and intervention group.</measure>
    <time_frame>Up to 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of included patients diagnosed with PE in the control and intervention group</measure>
    <time_frame>Up to 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients diagnosed with alternative diagnosis following clinical evaluation in the intervention and control group</measure>
    <time_frame>Up to 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients in the intervention and control group discharged to their own home following clinical evaluation</measure>
    <time_frame>Up to 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients in the reference and control group admitted to a cardiology department for telemetry monitoring (i.e. high risk PE) following clinical evaluation.</measure>
    <time_frame>Up to 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients in the reference and control group admitted to an intensive care unit following clinical evaluation</measure>
    <time_frame>Up to 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients in the reference and control group referred to supplementary CTPA or lung scintigraphy within 30 days after inclusion</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total costs related to diagnostic work up and hospital stay as assessed by HEAT 4.2</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subsequent cancer diagnosis in the intervention and control group within 6 months of inclusion</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Pulmonary Embolism</condition>
  <condition>Pulmonary Embolus/Emboli</condition>
  <arm_group>
    <arm_group_label>PoCUS group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients allocated to the PoCUS investigation arm will receive an ultrasound investigation resulting in either confirmation or dismissal of pulmonary embolism suspicion or requiring CTPA or VQ</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients allocated to the control group will continue with CTPA or VQ without PoCUS investigation</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Point-of-care-ultrasound examination</intervention_name>
    <description>The intervention consists of three ultrasound modalities:&#xD;
Cardiac ultrasound assessing signs of right ventricular strain or other obvious pathology.&#xD;
Deep venous ultrasound assessing presence of a deep venous thrombus&#xD;
Lung ultrasound assessing presence of pulmonary infarctions, pleural effusion, pneumothorax or interstitial syndrome.</description>
    <arm_group_label>PoCUS group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Referred or Admitted to an emergency department&#xD;
&#xD;
          -  Clinical suspicion of PE raised by physician requiring further diagnostic imaging&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refusal of informed consent&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Permanent mental disability&#xD;
&#xD;
          -  Age &lt;18 years&#xD;
&#xD;
          -  Diagnosis of PE within the last 6 months&#xD;
&#xD;
          -  Hemodynamic instability (systolic blood pressure &lt;90 mmHg for at least two consecutive&#xD;
             measurements)&#xD;
&#xD;
          -  Ultrasound of heart, lungs or deep veins performed prior to enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Casper Falster, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Odense University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christian B Laursen, Prof. MD</last_name>
    <role>Study Chair</role>
    <affiliation>Odense University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Casper Falster, MD</last_name>
    <phone>+4560139562</phone>
    <email>casper.falster@rsyd.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kolding Hospital</name>
      <address>
        <city>Kolding</city>
        <zip>6000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lasse Paludan, MD</last_name>
      <email>Lasse.Paludan.Bentsen@rsyd.dk</email>
    </contact>
    <investigator>
      <last_name>Lasse Paludan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick Mikkelsen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Casper Falster, MD</last_name>
      <phone>+4560139562</phone>
      <email>casper.falster@rsyd.dk</email>
    </contact>
    <investigator>
      <last_name>Casper Falster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefan Posth, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claus-Henrik Rasmussen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Henrik Ã˜mark, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Slagelse hospital</name>
      <address>
        <city>Slagelse</city>
        <zip>4200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Arvig, MD</last_name>
      <email>Michael.Dan.Arvig@rsyd.dk</email>
    </contact>
    <investigator>
      <last_name>Michael Arvig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Svendborg Hospital</name>
      <address>
        <city>Svendborg</city>
        <zip>5700</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristoffer Brockhattingen, MD</last_name>
      <email>Kristoffer.K.Brockhattingen@rsyd.dk</email>
    </contact>
    <investigator>
      <last_name>Kristoffer Brockhattingen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 12, 2021</study_first_submitted>
  <study_first_submitted_qc>May 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2021</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Casper Falster</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Ultrasound</keyword>
  <keyword>Diagnosis</keyword>
  <keyword>Ultrasonography</keyword>
  <keyword>Echocardiography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

